A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen

Phase 3

Completed

• Conditions: Non Small Cell Lung Cancer (NSCLC)
• Interventions: Drug: Nivolumab

• Registration Number: NCT02066636
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

The purpose of this study is to estimate the incidence and characterize the outcome of high grade, select adverse events in subjects with advanced or metastatic NSCLC treated with Nivolumab.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-02-14
• Study First Submitted QC: 2014-02-18
• Study First Posted: 2014-02-19
• Study Start: 2014-04-09
• Primary Completion: 2021-10-06
• Study Completion: 2021-10-06
• Status Verified: 2022-09
• Results First Submitted: 2022-09-29
• Results First Submitted QC: 2022-09-29
• Last Update Submitted: 2022-09-29
• Results First Posted: 2022-10-27
• Last Update Posted: 2022-10-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1428

Inclusion Criteria

1. Target Population

• Subjects with histologically-or cytologically-documented NSCLC [squamous (SQ) or nonsquamous (NSQ)] who present with Stage IIIB/Stage IV disease (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology), or with recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection or definitive chemoradiotherapy for locally advanced disease)
• Subjects must have experienced disease progression or recurrence during or after at least one systemic therapy for advanced or metastatic disease
• Each subsequent line of therapy must be preceded by disease progression. A switch of an agent within a regimen in order to manage toxicity does not define the start of a new line of therapy
• Maintenance therapy following platinum doublet-based chemotherapy is not considered as a separate regimen of therapy
• Subjects who received platinum-containing adjuvant, neoadjuvant or definitive chemoradiation therapy given for locally advanced disease, and developed recurrent (local or metastatic) disease within 6 months of completing therapy are eligible
• Subjects with recurrent disease >6 months after platinum-containing adjuvant, neoadjuvant or definitive chemoradiation therapy given for locally advanced disease, who also subsequently progressed during or after a platinum doublet-based regimen given to treat the recurrence are eligible
• Subjects with non-squamous histology must be tested for Epithelial Growth Factor Receptor (EGFR) mutations (including, but not limited to, deletions in exon 19 and exon 21 [L858R] substitution) and Anaplastic Lymphoma Kinase (ALK) rearrangement if tests have not been previously performed. Subjects with progressive disease during or after EGFR or ALK tyrosine kinase inhibitor (TKI) regimens are eligible. Subjects are eligible if genetic test results are indeterminate or if no tumor tissue is available or accessible for testing as long as they have received one prior systemic therapy
• Experimental therapies when given as separate regimen are considered as separate line of therapy
• Subjects must have measurable disease by CT or MRI per RECIST 1.1 criteria (radiographic tumor assessment performed within 28 days of first dose of study drug) or clinically apparent disease that the investigator can follow for response per RECIST 1.1
• Eastern Cooperative Oncology Arm (ECOG) performance status (PS)
• PS 0 to 1
• PS 2

Exclusion Criteria

1. Target Disease Exceptions

   • Subjects with active central nervous system (CNS) metastases are excluded
   • Subjects with carcinomatous meningitis

2. Medical History and Concurrent Diseases

   • Subjects with a history of interstitial lung disease
   • Subjects with active, known or suspected autoimmune disease
   • Subject whom participated in either arm of the following clinical trials CA209-017, CA209-057, CA209-026, and CA184-104 or received prior treatment with anti-programmed death 1 (PD-1) or anti-programmed death-ligand 1 (PDL1) experimental agents

3. Prohibited Treatments and/or Restricted Therapies

   • Ongoing or planned administration of anti-cancer therapies other than those specified in this study
   • Use of corticosteroids or other immunosuppressive medications

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort A: Nivolumab	Nivolumab	Nivolumab 3 mg/kg solution intravenous infusion over 30 minutes every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent
Cohort B: Nivolumab	Nivolumab	Nivolumab 3 mg/kg solution intravenous infusion over 30 minutes every two weeks until 1 year (52 weeks). Discontinue treatment and at progression, retreatment allowed

Primary Outcome Measures

Name	Time	Method
The Number of Participants With Treatment Related Select Adverse Events (Grade 3-4 and Grade 5)	From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)	A treatment related adverse event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that has a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.

Secondary Outcome Measures

Name	Time	Method
Median Time to Onset of Select Adverse Events (Grade 3-5)	From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)	The time from first dose to the first occurrence of any select adverse event of interest. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.
The Total Duration of All Immune Modulating Medications for Any Grade Select Adverse Events	From first dose first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)	The duration of time participants received medication meant to trigger an immune response for any select Adverse events of interest. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.
Median Time to Resolution of Select Adverse Events (Grade 3-5)	From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)	The time from the onset of any select adverse event of interest to its resolution or stabilization. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.
The Number of Participants Who Received Immune Modulating Medication (or Hormonal Replacement Therapy) for Any Grade Select Adverse Events	From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)	The number of participants receiving medication meant to trigger an immune response for any select Adverse events of interest. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.
The Number of Participants Who Received ≥ 40 mg Prednisone Equivalents for Any Grade Select Adverse Events	From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)	The number of participants receiving \> 40mg prednisone equivalents for any select adverse event of interest. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.
The Number of Participants With High Grade (Grade 3-4 and Grade 5) Select Adverse Events	From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)	An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.

Trial Locations

Locations (118)

Southern Cancer Center Pc; 🇺🇸 Mobile, Alabama, United States

Cancer Center Treatment Center of America; 🇺🇸 Goodyear, Arizona, United States

Arizona Oncology Associates; 🇺🇸 Sedona, Arizona, United States

Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope; 🇺🇸 Tucson, Arizona, United States

Comprehensive Blood And Cancer Center; 🇺🇸 Bakersfield, California, United States

Diablo Valley Oncology; 🇺🇸 Concord, California, United States

Saint Jude Heritage Medical Group Virginia K Crosson Cancer Center; 🇺🇸 Fullerton, California, United States

Ucla Hema/Onc-Santa Monica; 🇺🇸 Los Angeles, California, United States

Pacific Cancer Care; 🇺🇸 Monterey, California, United States

Sutter Cancer Center; 🇺🇸 Sacramento, California, United States

Scroll for more (108 remaining)